Eliem restructures, pauses ETX-155, focuses on Kv7 program, extends cash runway into 2027

Climb Bio, Inc.

Corporate reorganization: pause ETX-155 (GABA A PAM) development, focus on Kv7 program lead ETX-123; workforce reduction ~55% in H1 2023.
Andrew Levin appointed Executive Chairman after CEO Bob Azelby departure; Dr. Valerie Morisset continues as EVP R&D and CSO.
Cash, cash equivalents and marketable securities $123.6M as of Dec 31, 2022; expected to fund operations into 2027.
Net loss for FY2022: $45.2M ($7.8M Q4), compared to $47.5M in FY2021; R&D expenses $26.2M, G&A $18.9M.
IND-enabling studies for ETX-123 initiated; Phase 1 studies planned for H1 2024; preclinical data at March 2023 symposium.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Climb Bio, Inc. reported the quarter and year ended December 31, 2022 results: net income Net loss was $7.8 million for the three months ended December 31, 2022, and $45.2 million for the full year 2022.

Period: the quarter and year ended December 31, 2022
Net income: Net loss was $7.8 million for the three months ended December 31, 2022, and $45.2 million for the full year 2022
Result: reported results

Exact text from the filing

On March 6, 2023, Eliem Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Climb Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-006282

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.